Skip to main content

Table 3 n-3 PUFA-enriched versus standard parenteral lipid emulsions for parenteral nutrition: random effects meta-analysis

From: n-3 fatty acid-enriched parenteral nutrition regimens in elective surgical and ICU patients: a meta-analysis

Outcome

Studies

Patients (n)

Effect estimate

Mortality, overall RR

10

847

0.89 (0.59, 1.33)

   ICU patients

7

547

0.94 (0.61, 1.45)

   Non-ICU patients

3

300

0.58 (0.18, 1.84)

Infection rate, overall RR

11

919

0.61 (0.45, 0.84)*

   ICU patients

5

524

0.71 (0.45, 1.12)

   Non-ICU patients

6

395

0.53 (0.34, 0.82)*

Hospital LOS, overall MD

15

1169

-3.29 (-5.13, -1.45)*

   ICU patients

8

615

-5.17 (-8.35, -1.99)*

   Non-ICU patients

7

554

-1.86 (-3.13, -0.59)*

ICU LOS, MD

8

615

-1.92 (-3.27, -0.58)*

CRP, overall MD

7

432

-11.28 (-24.71, 2.16)

   ICU patients

6

405

-9.76 (-23.57, 4.04)

   Non-ICU patients

1

27

-46.00 (-108.12, 16.12)

IL-6 change, MD

3

105

37.70 (20.23, 55.16)*

Oxygenation index, MD

2

61

50.04 (10.99, 89.09)*

Serum lactate, MD

2

47

-0.29 (-1.38, 0.80)

LTB5, overall SMD

5

183

2.86 (1.22, 4.50)*

   ICU patients

3

120

3.35 (0.54, 6.16)*

   Non-ICU patients

2

63

2.14 (0.42, 3.85)*

LTB4, overall SMD

6

188

-0.47 (-1.18, 0.23)

   ICU patients

4

125

-0.85 (-1.42, -0.27)*

   Non-ICU patients

2

63

0.34 (-1.25, 1.92)

LTB ratio, overall MD

4

163

0.07 (0.05, 0.09)*

   ICU patients

2

100

0.11 (0.01, 0.22)*

   Non-ICU patients

2

63

0.06 (0.05, 0.07)*

EPA, overall SMD

9

271

4.12 (2.99, 5.25)*

   ICU patients

6

165

4.65 (2.70, 6.60)*

   Non-ICU patients

3

106

3.64 (2.65, 4.64)*

DHA, overall SMD

7

171

1.84 (0.65, 3.03)*

   ICU patients

4

65

2.82 (0.17, 5.46)*

   Non-ICU patients

3

106

1.33 (-0.11, 2.78)

Arachidonic acid, overall SMD

6

171

0.22 (-0.20, 0.64)

   ICU patients

3

65

0.35 (-0.14, 0.84)

   Non-ICU patients

3

106

0.14 (-0.62, 0.900

Alpha-tocopherol, overall MD

5

170

12.33 (8.73, 15.93)*

   ICU patients

3

104

10.08 (5.39, 14.76)*

   Non-ICU patients

2

66

15.25 (14.15, 16.35)*

Prothromin time (Quick), MD

2

300

0.43 (-2.62, 3.47)

Partial thromboplastin time, MD

2

65

10.71 (-30.08, 51.51)

Transfused blood units, SMD

2

209

-0.05 (-0.32, 0.22)

Platelet count

4

160

-6.32 (-31.40, 18.77)

Triglyceride level, overall MD

5

567

10.40 (-13.53, 34.34)

   ICU patients

4

368

14.16 (-13.12, 41.44)

   Non-ICU patients

1

199

-0.89 (-23.26, 21.48)

Serum creatinine, SMD

3

309

-3.01 (-7.11, 1.08)

Serum urea, SMD

2

53

-0.11 (-0.30, 0.08)

AST, overall MD

7

656

-10.05 (-18.81, -1.29)*

   ICU patients

4

373

-10.11 (-27.31, 7.10)

   Non-ICU patients

3

283

-8.37 (-17.36, 0.61)*

ALT, overall MD

7

482

-9.85 (-17.49, -2.21)*

   ICU patients

3

109

-18.18 (-21.68, -14.68)*

   Non-ICU patients

4

373

-4.97 (-9.62, -0.32)*

Serum bilirubin, overall MD

4

520

0.03 (-0.33, 0.40)

   ICU patients

3

321

0.12 (-0.42, 0.65)

   Non-ICU patients

1

199

-0.02 (-0.17, 0.13)

  1. Values in parentheses represent 95% CI. *Significant effect (P < 0.05). ALT, alanine aminotransferase; AST, aspartate aminotransferase; CRP, C-reactive protein; DHA,(%) docosahexaenoic acid content in serum/cellular membranes; EPA, (%) eicosapentaenoic acid content in serum/cellular membranes; (H) LOS, (Hospital) length of stay; ICU, intensive care unit; LTB, leukotrienes B ; LTB ratio, LTB5: LTB4; MD, mean difference; RR, relative risk; SMD, standardised mean difference.